Acelyrin (SLRN) Stock Forecast, Price Target & Predictions
SLRN Stock Forecast
Acelyrin stock forecast is as follows: an average price target of $10.50 (represents a 80.41% upside from SLRN’s last price of $5.82) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.
SLRN Price Target
The average price target for Acelyrin (SLRN) is $10.50 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $6.00. This represents a potential 80.41% upside from SLRN's last price of $5.82.
SLRN Analyst Ratings
According to 14 Wall Street analysts, Acelyrin's rating consensus is 'Buy'. The analyst rating breakdown for SLRN stock is 0 'Strong Buy' (0.00%), 7 'Buy' (50.00%), 7 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Acelyrin Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 16, 2024 | Derek Archila | Wells Fargo | $15.00 | $5.72 | 162.24% | 157.73% |
| Aug 14, 2024 | Samantha Semenkow | Citigroup | $6.00 | $4.06 | 47.78% | 3.09% |
| Mar 20, 2024 | Derek Archila | Wells Fargo | $13.00 | $8.32 | 56.25% | 123.37% |
The latest Acelyrin stock forecast, released on Oct 16, 2024 by Derek Archila from Wells Fargo, set a price target of $15.00, which represents a 162.24% increase from the stock price at the time of the forecast ($5.72), and a 157.73% increase from SLRN last price ($5.82).
Acelyrin Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 2 | 3 |
| Avg Price Target | $15.00 | $10.50 | $11.33 |
| Last Closing Price | $5.82 | $5.82 | $5.82 |
| Upside/Downside | 157.73% | 80.41% | 94.67% |
In the current month, the average price target of Acelyrin stock is $15.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 157.73% increase as opposed to Acelyrin's last price of $5.82. This month's average price target is up 42.86% compared to last quarter, and up 32.39% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 16, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Sep 25, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 14, 2024 | Citigroup | Neutral | Neutral | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 14, 2024 | H.C. Wainwright | Buy | Neutral | Downgrade |
| Jul 08, 2024 | Wells Fargo | - | Overweight | Upgrade |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| May 10, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 30, 2023 | Piper Sandler | - | Overweight | Initialise |
Acelyrin's last stock rating was published by Wells Fargo on Oct 16, 2024. The company gave SLRN a "Overweight" rating, the same as its previous rate.
Acelyrin Financial Forecast
Acelyrin Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Acelyrin's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SLRN's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Acelyrin EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict SLRN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Acelyrin's previous annual EBITDA (undefined) of $NaN.
Acelyrin Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-60.98M | $-51.56M | $-50.57M | $-54.54M | $-92.22M | $-79.20M | $-77.35M |
| High Forecast | $-60.98M | $-51.56M | $-50.57M | $-54.54M | $-92.22M | $-53.74M | $-77.35M |
| Low Forecast | $-60.98M | $-51.56M | $-50.57M | $-54.54M | $-92.22M | $-101.83M | $-77.35M |
| Surprise % | - | - | - | - | - | - | - |
Acelyrin's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SLRN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Acelyrin SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Acelyrin's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SLRN last annual SG&A of $NaN (undefined).
Acelyrin EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.61 | $-0.52 | $-0.51 | $-0.55 | $-0.93 | $-0.80 | $-0.78 |
| High Forecast | $-0.61 | $-0.52 | $-0.51 | $-0.55 | $-0.93 | $-0.54 | $-0.78 |
| Low Forecast | $-0.61 | $-0.52 | $-0.51 | $-0.55 | $-0.93 | $-1.03 | $-0.78 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Acelyrin's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SLRN previous annual EPS of $NaN (undefined).
SLRN Forecast FAQ
Is Acelyrin a good buy?
Yes, according to 14 Wall Street analysts, Acelyrin (SLRN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 50.00% of SLRN's total ratings.
What is SLRN's price target?
Acelyrin (SLRN) average price target is $10.5 with a range of $6 to $15, implying a 80.41% from its last price of $5.82. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Acelyrin stock go up soon?
According to Wall Street analysts' prediction for SLRN stock, the company can go up by 80.41% (from the last price of $5.82 to the average price target of $10.5), up by 157.73% based on the highest stock price target, and up by 3.09% based on the lowest stock price target.
Can Acelyrin stock reach $9?
SLRN's average twelve months analyst stock price target of $10.5 supports the claim that Acelyrin can reach $9 in the near future.
What is Acelyrin's current price target trend?
1 Wall Street analyst forecast a $15 price target for Acelyrin (SLRN) this month, up 157.73% from its last price of $5.82. Compared to the last 3 and 12 months, the average price target increased by 80.41% and increased by 94.67%, respectively.
What are Acelyrin's analysts' financial forecasts?
Acelyrin's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-249M (high $-223M, low $-271M), average SG&A $0 (high $0, low $0), and average EPS is $-2.509 (high $-2.252, low $-2.737). SLRN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-218M (high $-218M, low $-218M), average SG&A $0 (high $0, low $0), and average EPS is $-2.195 (high $-2.195, low $-2.195).